Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

NCT05077956 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT05077956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
Lead sponsor
Providence Health & Services
Phase
Observational
Overall status
Withdrawn
Start date
October 19, 2021
Completion date
October 25, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing multiple sclerosis